Literature DB >> 23197022

Cyclin-dependent kinase inhibitors move into Phase III.

Malini Guha.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23197022     DOI： 10.1038/nrd3908

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  25 in total

1.  A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations.

Authors:  Corina Hutterer; Jan Eickhoff; Jens Milbradt; Klaus Korn; Isabel Zeitträger; Hanife Bahsi; Sabrina Wagner; Gunther Zischinsky; Alexander Wolf; Carsten Degenhart; Anke Unger; Matthias Baumann; Bert Klebl; Manfred Marschall
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

2.  Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains.

Authors:  Mathew P Martin; Sanne H Olesen; Gunda I Georg; Ernst Schönbrunn
Journal:  ACS Chem Biol       Date:  2013-09-10       Impact factor: 5.100

3.  Serine 350 of human pregnane X receptor is crucial for its heterodimerization with retinoid X receptor alpha and transactivation of target genes in vitro and in vivo.

Authors:  Yue-Ming Wang; Sergio C Chai; Wenwei Lin; Xiaojuan Chai; Ayesha Elias; Jing Wu; Su Sien Ong; Satyanarayana R Pondugula; Jordan A Beard; Erin G Schuetz; Su Zeng; Wen Xie; Taosheng Chen
Journal:  Biochem Pharmacol       Date:  2015-06-25       Impact factor: 5.858

4.  Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

Authors:  Ernst Schonbrunn; Stephane Betzi; Riazul Alam; Mathew P Martin; Andreas Becker; Huijong Han; Rawle Francis; Ramappa Chakrasali; Sudhakar Jakkaraj; Aslamuzzaman Kazi; Said M Sebti; Christopher L Cubitt; Anthony W Gebhard; Lori A Hazlehurst; Joseph S Tash; Gunda I Georg
Journal:  J Med Chem       Date:  2013-05-06       Impact factor: 7.446

5.  Development of CDK2 and CDK5 Dual Degrader TMX-2172.

Authors:  Mingxing Teng; Jie Jiang; Zhixiang He; Nicholas P Kwiatkowski; Katherine A Donovan; Caitlin E Mills; Chiara Victor; John M Hatcher; Eric S Fischer; Peter K Sorger; Tinghu Zhang; Nathanael S Gray
Journal:  Angew Chem Int Ed Engl       Date:  2020-06-03       Impact factor: 15.336

Review 6.  The molecular balancing act of p16(INK4a) in cancer and aging.

Authors:  Kyle M LaPak; Christin E Burd
Journal:  Mol Cancer Res       Date:  2013-10-17       Impact factor: 5.852

7.  Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells.

Authors:  Inge The; Suzan Ruijtenberg; Benjamin P Bouchet; Alba Cristobal; Martine B W Prinsen; Tim van Mourik; John Koreth; Huihong Xu; Albert J R Heck; Anna Akhmanova; Edwin Cuppen; Mike Boxem; Javier Muñoz; Sander van den Heuvel
Journal:  Nat Commun       Date:  2015-01-06       Impact factor: 14.919

8.  Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.

Authors:  Yuh-Ying Yeh; Rong Chen; Joshua Hessler; Emilia Mahoney; Amy M Lehman; Nyla A Heerema; Michael R Grever; William Plunkett; John C Byrd; Amy J Johnson
Journal:  Oncotarget       Date:  2015-02-20

9.  Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(iii) dithiocarbamates.

Authors:  Randall T Mertens; Sean Parkin; Samuel G Awuah
Journal:  Chem Sci       Date:  2020-09-18       Impact factor: 9.825

10.  Integrative bioinformatics approaches to map key biological markers and therapeutic drugs in Extramammary Paget's disease of the scrotum.

Authors:  Fatima Noor; Muhammad Hamzah Saleem; Jen-Tsung Chen; Muhammad Rizwan Javed; Wafa Abdullah Al-Megrin; Sidra Aslam
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.752
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.